The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 195-201

  M Goldenberg, David ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibodies; Non Hodgkin's Lymphoma; Radioimmunotherapy

Indexed keywords

CD20 ANTIGEN; CD22 ANTIGEN; EPRATUZUMAB Y 90; HLA DR ANTIGEN; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG TARGETING; HUMAN; NONHODGKIN LYMPHOMA; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY;

EID: 0034970692     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00108-1     Document Type: Conference Paper

References (43)

1. 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL)
2. HAMA interference with murine monoclonal antibody-based immunoassays
3. Revised Nuclear Regulatory Commission's regulations for release of patients administered radioactive materials: outpatient iodine 131 anti-B1 therapy
4. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications
5. Zevalin radioimmunotherapy (RIT) is effective and safe without imaging and biodistribution dosimetry in patients with rituximab-refractory follicular lymphoma (F-NHL)
6. Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma
7. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
8. 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL)
9. 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL)
10. Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation
11. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
12. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cel rescue
13. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience
14. A phase I/II trial of iodine-131-tositumomab (anti-CD-20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
15. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapse or refractory non-Hodgkin's lymphoma
16. Zevalin™ radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma
17. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
18. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL)
19. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
20. Immunotherapy of NHL with Epratuzumab (anti-CD22 monoclonal antibody): Excellent tolerability with objective responses
21. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma
22. Lymphoma imaging with a new technetium-99m labeled antibody, LL2
23. Initial clinical results with technetium-99m- labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas
24. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2
25. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
26. Treatment on non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
27. 131iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
28. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
29. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
30. Updated results of radioimmunotherapy of relapsed refractory non-hodgkin's lymphoma with conventional and stem cell supported doses of 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody
31. 186Re-hLL2
32. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
33. Radioimmunotherapy of lymphoma: a UC Davis experience
34. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
35. 1311-Lym-1 antibody
36. 67Copper-2-iminothiolane-6-[p-(bromocetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma
37. 131I-Lym-1
38. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody
39. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning